Development of novel gene therapeutics for inflammation-induced bone loss
AssigneeUniversity of Massachusetts
InventorsJae-Hyuck Shim, Guangping Gao, Jun Xie, Yeon-Suk Yang
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Massachusetts
InventorsJae-Hyuck Shim, Guangping Gao, Jun Xie, Yeon-Suk Yang
Estimating the term…
Aspects of the disclosure relate to compositions and methods for reding inflammation and/or inhibiting bone loss (e.g., bone loss induced by inflammation). In some embodiments, the disclosure provides isolated nucleic acids and expression constructs (e.g., rAAVs, etc.) that encode one or more of the following transgenes: inhibitory nucleic acids targeting Schnurri 3 (SHN3), inhibitory nucleic acids targeting Cathepsin K (CTSK), inhibitory nucleic acids targeting sclerostin (SOST), inhibitory nucleic acids targeting receptor activator of NF-κβ (RANK), inhibitory nucleic acids targeting receptor activator of NF-κβ ligand (RANKL), soluble TNF-α Receptor 2 (sTNFR2), and soluble IL-1 Receptor Antagonist (sIL1Rα). In some embodiments, compositions described by the disclosure are useful for treating diseases associated with inflammation, for example rheumatoid arthritis (RA).
An isolated nucleic acid comprising a transgene comprising an osteoclast (OC)-specific promoter or an osteoblast (OB)-specific promoter operably linked to a nucleic acid sequence encoding one or more inhibitory nucleic acids targeting sclerostin (SOST), schnurri-3 (SHN3), cathepsin K (CTSK), receptor activator of NF-κβ, (RANK) and/or receptor activator of NF-κβ ligand (RANKL).
(canceled)
(canceled)
An isolated nucleic acid comprising a transgene encoding a first inhibitory nucleic acid targeting a gene selected from SHN3, CTSK, SOST, RANK, and RANKL;
18-29. (canceled)
An isolated nucleic acid comprising or encoding a sequence set forth in any one of SEQ ID NOs:
31-33. (canceled)
-39. (canceled)
43-51. (canceled)
Dependencies are inferred from the claim text.